Skip to main content
dna sequence computer

Translational Research and Interventional Oncology Research Program

The Translational Research and Interventional Oncology Research Program translates advances in mechanism-based research into improved detection methods and therapies for cancer. With a primary focus on lung cancer, melanoma and leukemia/lymphoma, the program is dedicated to new discoveries in early detection and molecular oncology, and genotype-driven early phase trials for all cancer types.

RESEARCH THEMES

The Translational Research and Interventional Oncology program is dedicated to translating our understanding of the molecular mechanisms of oncogenesis and tumor progression into novel therapeutic strategies for cancer. 

Developing early phase clinical trials for therapies directed at genetic changes in tumors

Investigating why some tumors become resistant to genetically targeted therapies and developing new strategies to prevent and overcome resistance

Applying and enhancing immune strategies and cellular therapies for cancer

Developing and evaluating screening methods and biomarkers for early detection of lung cancers

Meet the Program Members

The Translational Research and Interventional Oncology Program is the largest of the cancer center's formal research programs, with more than 50 members representing a range of clinical and translational cancer research areas. The program is led by Madan Jagasia, M.B.B.S., Young Kim, M.D., Ph.D., and Christine Lovly, M.D., Ph.D.

Featured Publications

Program News

June 7, 2019

Immunotherapy helping 87-year-old man stay on the job

Immunotherapy is helping cancer patient Roszell Mack Jr. to continue going to his job on a Kentucky horse farm.
April 25, 2019

Pathways of radiosensitization

Austin Kirschner, MD, PhD, and colleagues have studied the mechanism of radiation sensitization for enzalutamide using multiple models of human prostate cancer.
April 25, 2019

Study reframes approach to targeted therapy resistance

A recent study provides clinicians genomic guidance for surveillance of targeted therapy resistance in patients with EGFR-mutant non-small cell lung cancer — and more importantly — another drug option when resistance occurs.